BillionToOne has become a newly minted public company, raising $273.1m in an upsized initial public offering (IPO), despite the longest government shutdown in US history hampering those wishing to join the stock exchange. The US-based company sold around 4.5 million shares of its common stock at $60 each. The molecular test developer initially offered around 3.8 million shares that were expected to fall between $49 and $55 each. BillionToOne’s IPO has given it a market valuation at around $2.6bn. The mol ...